Bioeconomy,
Biotechnology,
Synthetic Biology,
Biosecurity
Dr. Sarah R. Carter is a Senior Fellow for the Bioeconomy at the Federation of American Scientists. In recent years, she has been an independent consultant focused on societal and policy issues related to the bioeconomy, including government oversight, industry practices, responsible innovation, and biosecurity. Previously, she worked in the Policy Center of the J. Craig Venter Institute and at the White House Office of Science and Technology Policy (OSTP). She is a former AAAS S&T Policy Fellow and a former Mirzayan S&T Fellow of the National Academies. She earned her Ph.D. from the University of California, San Francisco, and her bachelor’s degree from Duke University.
In the quest for sustainable energy and materials, biomass emerges as a key player, bridging the gap between the energy sector and the burgeoning U.S. and regional bioeconomies.
While the U.S. government grapples with the definition of the bioeconomy and what sectors it does and does not contain, another definitional issue needs to be addressed: What does sustainability mean in a bioeconomy?
The landscape of biosecurity risks related to AI is complex and rapidly changing, and understanding the range of issues requires diverse perspectives and expertise. Here are five promising ideas that match the diversity of challenges that AI poses in the life sciences.
We sat down with MicroByre CEO Dr. Sarah Richardson to talk about biomanufacturing, corn sugar’s pitfalls, and more.
To develop an overarching framework that includes addressing bio-related risks, Congress, federal agencies, and non-governmental AI stakeholders must work together.
To achieve a durable and strategic interagency approach to the bioeconomy, OSTP should establish a Bioeconomy Initiative Coordination Office to coordinate strategic U.S. government investments in the bioeconomy.
The past year has been an exciting time for the bioeconomy as U.S. government agencies work to update their approaches and improve coordination to better support bio-based products and processes.
Over the past year, there have been significant policy advances related to the US bioeconomy—the part of the economy driven by the life sciences and biotech, and enabled by engineering, computing, and information science.1 The bioeconomy includes a wide range of products and processes, from mRNA vaccines and drought-resistant crops to microbial fertilizers and bioindustrial fermentation. […]